author-photo

Barbara Uscinska

Medical Research Council

25

Papers

1866

Citations

Citation Trend

Filter By

Papers (22) Sort By

Journal Conference Others

BA08: An open-label, single-arm, non-randomised, phase 2 trial of cisplatin, methotrexate and vinblastine (CMV) for pure squamous cell cancer of the urinary tract

2019 PLOS ONE
Show All
- Source
- Cite
- Save
Citations (3)
Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: A report from the European Osteosarcoma Intergroup

2012 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (40)
A Phase II Trial of Continuous 5-Fluorouracil in Recurrent or Metastatic Transitional Cell Carcinoma of the Urinary Tract

2009 Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (7)
The more it hurts, the better it works? Chemotherapy toxicity as a predictor of outcome from osteosarcoma: a report from the European Osteosarcoma Intergroup.

2008
Show All
- Source
- Cite
- Save
Citations (1)
Improvement in Histologic Response But Not Survival in Osteosarcoma Patients Treated With Intensified Chemotherapy: A Randomized Phase III Trial of the European Osteosarcoma Intergroup

2007 Journal of the National Cancer Institute
Show All
- Source
- Cite
- Save
Citations (260)
Doxorubicin and cisplatin chemotherapy in high-grade spindle cell sarcomas of the bone, other than osteosarcoma or malignant fibrous histiocytoma: a European Osteosarcoma Intergroup Study

2005 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (36)
Phase III Trial of Epirubicin Plus Paclitaxel Compared With Epirubicin Plus Cyclophosphamide As First-Line Chemotherapy for Metastatic Breast Cancer: United Kingdom National Cancer Research Institute Trial AB01

2005 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (52)
Chemotherapy at standard or increased dose intensity in patients with operable osteosarcoma of the extremity: A randomised controlled trial of the European Osteosarcoma Intergroup (ISRCTN 86294690).

2003
Show All
- Source
- Cite
- Save
Citations (7)
693 Does increasing dose intensity in patients with operable osteosarcoma of the extremity improve outcome? A randomised controlled trial of the European Osteosarcoma Intergroup (EOI)

2003 Ejc Supplements
Show All
- Source
- Cite
- Save
Citations (1)
Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial

2002 The Lancet
Show All
- Source
- Cite
- Save
Citations (442)